Mandate

VINGE ADVISES WILLIS IN ACQUISITION OF MAX MATTHIESSEN

June 13, 2014

Vinge assists global risk adviser, insurance and reinsurance broker Willis Group Holdings plc in connection with its acquisition of a controlling stake in Max Matthiessen. Willis acquires approximately 75 % of the Swedish employee benefits advisor for approximately SEK 1.357 billion from Altor Fund III (50 %) and employees (25 %). Approximately 25 % is retained by employees.
 
Willis is listed on NYSE and operates on every continent with more than 18,000 employees in over 400 offices. Willis Sweden has 140 employees in four offices and is headquartered in Stockholm.
 
Max Matthiessen operates in retirement savings, health plans and personal insurance. The company has around 420 employees in 23 locations across Sweden. Gross turnover in 2013 exceeded SEK 1 billion. The combined business of Willis and Max Matthiessen will create the biggest risk adviser and broker in the Nordic region.
 
The acquisition is conditional upon customary regulatory approvals and conditions to closing.
 
Vinge’s team consisted of among others responsible partner Carl Gustaf De Geer, partner Malin Ohlin, project manager Peter Sundgren and associates Filip Brosset and Sofie Bjärtun (M&A), as well as associates Axel Hedberg (financial regulatory), Nina Farrahi (compliance), Emil Fahlén Godö (competition law) and Evelina Tejle (employment law).

 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024